Live Feeds
โ— LIVE Updated 20m ago ยท 22 sources tracked

FDA tells GLP-1 makers to warn of potential vision loss side effect

The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 drugs including Ozempic, Wegovy, Zepbound and Mounjaro to add warnings about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) that can cause sudden, permanent vision loss. The agency said it identified a potential safety signal after reviewing adverse-event reports and published studies. Drugmakers must update prescribing information and patient medication guides to reflect the risk. The drugs remain on the market and the FDA has not recommended patients stop taking them.

๐ŸŽ™๏ธ

Listen to Live Briefing

Real-time synthesized voice briefing ยท Live Feeds Desk

โฑ ~3 min
Speed:
RSS Source map (22)
โšก Key Developments & Real-Time Context
Text size:
  • โœ“ FDA ordered manufacturers of GLP-1 drugs to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION).
  • โœ“ Affected drugs include Ozempic, Wegovy, Zepbound and Mounjaro.
  • โœ“ NAION can cause sudden, permanent vision loss often in one eye.
  • โœ“ The drugs remain approved and on the market; FDA did not advise patients to stop taking them.
๐Ÿ›ก๏ธ Source Corroboration: 22 independent reporting domains (96% confidence) โฑ Read time: ~3 min

What changed

The FDA formally mandated new boxed label warnings for NAION risk across the entire GLP-1 class, whereas previously no such warning existed.

Live updates

  1. FDA orders vision-loss warning on GLP-1 weight-loss drugs

    The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 drugs including Ozempic, Wegovy, Zepbound and Mounjaro to add warnings about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) that can cause sudden, permanent vision loss. The agency said it identified a potential safety signal after reviewing adverse-event reports and published studies. Drugmakers must update prescribing information and patient medication guides to reflect the risk. The drugs remain on the market and the FDA has not recommended patients stop taking them.

    Why it matters

    GLP-1 receptor agonists have become blockbuster treatments for type 2 diabetes and obesity, with millions of prescriptions written annually. NAION, often described as an "eye stroke," results from reduced blood flow to the optic nerve and typically causes painless, irreversible vision loss in one eye. Until now, labels listed common side effects such as nausea and pancreatitis but did not highlight this specific ocular risk. The FDA action follows months of scrutiny after case reports and observational studies suggested a possible association.

    What is confirmed

    • FDA ordered manufacturers of GLP-1 drugs to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION).
    • Affected drugs include Ozempic, Wegovy, Zepbound and Mounjaro.
    • NAION can cause sudden, permanent vision loss often in one eye.
    • The drugs remain approved and on the market; FDA did not advise patients to stop taking them.

    Still unconfirmed

    • The absolute risk of NAION for GLP-1 users is higher than for the general population.
    • The warning will significantly reduce new prescriptions for these medications.

    What to watch next

    • FDA safety communication with quantitative incidence data
    • Manufacturer label revision timelines and exact warning language
    • Results of ongoing epidemiological studies on GLP-1 and NAION association
    Sources used for this update (21)
    1. finance.yahoo.com โ€” Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. nypost.com โ€” New York Post โ€“ Breaking News, Top Headlines, Photos & Videos
    3. www.koreajoongangdaily.com โ€” Korea JoongAng Daily | Korean news in English
    4. www.zerohedge.com โ€” Futures Rise, Oil Slides As Iran's Supreme Leader Talks Peace And Shrugs Off Ras Tanura Attack
    5. www.medicaldaily.com โ€” Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
    6. english.mathrubhumi.com โ€” 13 killed as Russian drone strikes two trains at Ukrainian railway station
    7. news.northeastern.edu โ€” Is It Still Safe To Travel By Train In Europe?
    8. Financial Times โ€” US regulator orders makers of weight-loss drugs to carry blindness risk warning
    9. CNN โ€” US FDA orders new eye risk warnings for Ozempic, Zepbound
    10. NBC News โ€” FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
    11. STAT โ€” FDA warns GLP-1 drugs carry potential risk of rare eye condition
    12. AP News โ€” FDA adds rare vision-loss warning to popular GLP-1 drugs
    confidence 96%
๐Ÿ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community